Andrianto Andrianto, Hermawan Hanestya O, Harsoyo Primasitha M, Zaini Bagas Si, Muhammad Akbar R
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Department of Cardiology and Vascular Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Narra J. 2024 Aug;4(2):e681. doi: 10.52225/narra.v4i2.681. Epub 2024 Jul 15.
Obesity has emerged as a worldwide health concern due to its increasing prevalence. Adipocytes have the ability to express angiotensin-converting enzyme 2 receptors (ACE2) and several adipocytokines. These expressions could lead to the activation of a cytokine storm, which in turn promotes the development of cardiovascular diseases. The aim of this study was to investigate the impact of perindopril and losartan exposure on the ACE2 and interleukin 6 (IL-6) levels in adipocyte cells. This study used an in vivo true experimental design utilizing a post-test-only control group. A total of 24 adult male albino rats were divided into four groups, one group served as the non-obese (negative control), while the other three groups were obese: (1) the positive control (untreated obese rats); (2) perindopril group (2 mg/kg BW/day orally for 4 weeks); and (3) losartan group (20 mg/kg BW/day for 4 weeks). Afterwards, the rats were euthanized, and the visceral fat tissue were obtained during dissection. The levels of ACE2 and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA). Losartan administration in obese rats resulted in a notable elevation in ACE2 levels compared to both the perindopril group (losartan vs perindopril, =0.011) and the positive control (=0.004). In addition, the treatment of perindopril and losartan in obese rats resulted in a significant reduction in IL-6 levels when compared to the positive control (perindopril vs positive control, 0.020; losartan vs positive control, 0.002, respectively). This study provides insight into the administration of perindopril and losartan, which could suppress the pro-inflammatory (IL-6) but increase the ACE2 levels in adipose tissue.
由于肥胖症患病率不断上升，它已成为一个全球性的健康问题。脂肪细胞能够表达血管紧张素转换酶2受体（ACE2）和多种脂肪细胞因子。这些表达可能导致细胞因子风暴的激活，进而促进心血管疾病的发展。本研究的目的是调查培哚普利和氯沙坦暴露对脂肪细胞中ACE2和白细胞介素6（IL-6）水平的影响。本研究采用了仅在后测时设置对照组的体内真实实验设计。总共24只成年雄性白化大鼠被分为四组，一组作为非肥胖组（阴性对照），而其他三组为肥胖组：（1）阳性对照组（未治疗的肥胖大鼠）；（2）培哚普利组（口服2mg/kg体重/天，持续4周）；（3）氯沙坦组（20mg/kg体重/天，持续4周）。之后，对大鼠实施安乐死，并在解剖过程中获取内脏脂肪组织。使用酶联免疫吸附测定（ELISA）测量ACE2和IL-6的水平。与培哚普利组（氯沙坦组与培哚普利组比较，P=0.011）和阳性对照组（P=0.004）相比，肥胖大鼠服用氯沙坦后ACE2水平显著升高。此外，与阳性对照组相比，肥胖大鼠服用培哚普利和氯沙坦后IL-6水平显著降低（培哚普利组与阳性对照组比较，P=0.020；氯沙坦组与阳性对照组比较，P分别为0.002）。本研究为培哚普利和氯沙坦的给药提供了见解，它们可以抑制促炎因子（IL-6），但会增加脂肪组织中的ACE2水平。
